[Industry]

Shanghai-based Harbour BioMed Deepens US Partnership

by Lu Feiran
January 22, 2026
Share Article:

Shanghai-based Harbour BioMed (stock sticker: 2142.HK) has taken an equity stake in US biotech firm Spruce Biosciences, signaling a shift by Chinese drug developers toward deeper strategic partnerships beyond one-off licensing deals. According to a comopany filing with the Hong Kong Stock Exchange, Harbour exercised warrants granted under a prior licensing agreement, acquiring approximately a 3.8% stake in Spruce.

The warrants were issued when Harbour's subsidiary, HBM Alpha Therapeutics, entered into a licensing agreement last year that granted Spruce the rights to develop and commercialize Harbour's early-stage therapy for rare hormone disorders. Harbour founder and chief executive Wang Jingsong said the move represents "a significant milestone," marking a transition from a conventional licensor-licensee relationship to a more strategic partnership.


#Shanghai
Share Article:

In Case You Missed It...

Putuo Builds on Four Decades of Trade to Become Shanghai's Nonferrous Metals Hub
FEATURED
[GENERAL]
Putuo Builds on Four Decades of Trade to Become Shanghai's Nonferrous Metals Hub
@ Hu MinLineNov 7, 2026
Dior Showcases Creativity And Sustainability AT 2026 CIIE
[General]
Dior Showcases Creativity And Sustainability AT 2026 CIIE
At the 9th China International Import Expo (CIIE), running in Shanghai from 5 to 10 November 2026, Dior continues the cultural and artistic dialogue that unites it with China.
[China's Next Order] How Foreign Exporters Need to Position Themselves to Succeed in China Market
[In Perspective]
[China's Next Order] How Foreign Exporters Need to Position Themselves to Succeed in China Market
China's import market is in the throes of transformation. Adapting to changing consumer and manufacturing trends is the key to success.
Chinese Tech Stocks Crumble as US Selloff Hits Asia, Japan Enters Bear Market
[Money]
Chinese Tech Stocks Crumble as US Selloff Hits Asia, Japan Enters Bear Market
Fears of a crippled AI boom after US elections soured investor sentiment toward companies at the forefront of new technologies.
AISHAISH